Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MET-875o
- Development stage
- Preclinical
- Lead developer
- D&D Pharmatech
- Modality
- Peptides
- Administration
- Oral
01
Overview
MET-875o is an oral peptide dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Developed by D&D Pharmatech using their proprietary ORALINK technology, the drug is designed for the treatment of obesity. The ORALINK platform aims to improve the oral bioavailability of peptide drugs, which are typically administered via injection. By targeting both GLP-1 and GIP receptors, MET-875o seeks to leverage the synergistic effects of these incretin hormones on appetite regulation and glucose metabolism. It is currently in the IND-enabling stage of development.
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on MET-875o.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MET-875o.